Decreased collagen mRNA and regression of cardiac fibrosis in the ventricular myocardium of the tight skin mouse following thyroid hormone treatment

1992 ◽  
Vol 26 (6) ◽  
pp. 603-607 ◽  
Author(s):  
J. Yao ◽  
M. Eghbali
Keyword(s):  
Thyroid Hormone ◽  
Cardiac Fibrosis ◽  
Hormone Treatment ◽  
Ventricular Myocardium ◽  
Collagen Mrna ◽  
Tight Skin

Linear modulation of serum thyrotrophin by thyroid hormone treatment in hypothyroidism

1980 ◽  
Vol 95 (4) ◽  
pp. 472-478 ◽  
Author(s):  
A. Eugene Pekary ◽  
Jerome M. Hershman ◽  
Clark T. Sawin
Keyword(s):  
Thyroid Hormone ◽  
Hormone Replacement ◽  
Hormone Treatment ◽  
Significant Negative Correlation ◽  
Thyroid Hormone Replacement ◽  
Basal Serum ◽  
Thyroid Hormone Levels ◽  
Peak Versus ◽  
Hypothyroid Patients ◽  
Serum Tsh

Abstract. Basal serum TSH and the peak TSH response to a 500 μg TRH bolus were measured in 57 euthyroid and in 29 hypothyroid subjects either receiving graded thyroid hormone replacement or acutely removed from full replacement therapy. Serum TSH, total T4 and T3 were determined by sensitive radioimmunoassay methods. The peak versus basal TSH data for hypothyroid patients were linear within individuals. The regression slope of the peak versus basal TSH data for all hypothyroid subjects did not differ significantly from the corresponding slope for all euthyroid subjects. Basal and peak TSH versus T3 and T4 data for hypothyroid patients were also linear within each individual. Moreover, the regression of the basal TSH values averaged over the non-replacement to full replacement state against the TSH versus T3 slope had a significant negative correlation. This trend leads to an array of regression lines which average to the familiar hyperbolic relationship between thyrotrophin and thyroid hormone levels in man.

Growth hormone treatment in children with idiopathic short stature: correlation of growth response with peripheral thyroid hormone action

2011 ◽  
Vol 74 (3) ◽  
pp. 346-353 ◽  
Author(s):  
Sebastián Susperreguy ◽  
Liliana Muñoz ◽  
Natalia Y. Tkalenko ◽  
Ivan D. Mascanfroni ◽  
Vanina A. Alamino ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Thyroid Hormone ◽  
Short Stature ◽  
Growth Response ◽  
Growth Hormone Treatment ◽  
Hormone Treatment ◽  
Idiopathic Short Stature ◽  
Hormone Action ◽  
Thyroid Hormone Action

scholarly journals Thyroid Hormone Treatment to Mend a Broken Heart

2008 ◽  
Vol 93 (4) ◽  
pp. 1172-1174 ◽  
Author(s):  
Irwin Klein ◽  
Sara Danzi
Keyword(s):  
Thyroid Hormone ◽  
Hormone Treatment

scholarly journals Differential modulation of expression of the two acylphosphatase isoenzymes by thyroid hormone

1995 ◽  
Vol 311 (2) ◽  
pp. 567-573 ◽  
Author(s):  
P Chiarugi ◽  
G Raugei ◽  
R Marzocchini ◽  
T Fiaschi ◽  
C Ciccarelli ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Thyroid Hormone ◽  
State Level ◽  
K562 Cells ◽  
Hormone Treatment ◽  
Differential Regulation ◽  
Rapid Decrease ◽  
Differential Modulation ◽  
Hormone Administration ◽  
Specific Mrna

The modulation of expression of the skeletal muscle and erythrocyte acylphosphatase isoenzymes by thyroid hormone has been investigated. Our results indicate a differential regulation of the two enzymic isoforms by tri-iodothyronine (T3) in K562 cells in culture: an increase in the specific mRNA during T3-stimulation is shown only for the skeletal muscle isoenzyme. A fast and transient T3 induction of the accumulation of the specific mRNA can be observed, reaching a maximum 8 h after hormone treatment and then rapidly decreasing almost to the steady-state level after 24 h. A nuclear run-on assay was performed to explore the mechanisms of this regulation. These studies indicate that T3 induction of skeletal muscle acylphosphatase mRNA is due, at least in part, to a fast and transient increase in the rate of gene transcription, within 4 h after hormone administration. A very rapid decrease is then observed within a further 2 h. T3-dependent accumulation of the mRNA for the skeletal muscle acylphosphatase requires ongoing protein synthesis, as confirmed by inhibition with cycloheximide or puromycin. These findings indicate that the transcriptional regulation of the gene may be indirect.

Abstract 5939: Inhomogenous Regulation Of Matrix Metalloproteinases And Their Endogenous Inhibitors Intensifies Cardiac Fibrosis In Zucker Diabetic Fatty Rats

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Tobias Graf ◽  
Karoline Hanke ◽  
Hendrik Sager ◽  
Sabine Fredersdorf ◽  
Christof Burgdorf ◽  
...  
Keyword(s):  
Visual Field ◽  
Matrix Metalloproteinases ◽  
Cardiac Fibrosis ◽  
Ventricular Myocardium ◽  
Left Ventricular ◽  
Heart Weight ◽  
Left Ventricular Myocardium ◽  
Regulation Of Expression ◽  
Endogenous Inhibitors ◽  
Zucker Diabetic Fatty Rats

AIM: Experimental and clinical studies have demonstrated that matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) are upregulated in dilated failing hearts and involved in the development and progression of myocardial remodelling. However, changes in MMP and TIMP protein levels or activity in the diabetic heart has not yet been described. METHODS: Untreated male Zucker diabetic fatty (ZDF) and Zucker lean (ZL) rats were sacrificed at the age of 6 (prediabetic), 22 (diabetic) and 42 (late diabetes) weeks (wks) and body weight, total heart weight and plasma glucose were measured (n=7, each group). MMP-2, MMP-9 and TIMP-1 were quantified by Western blot analysis of total protein isolated from left ventricular tissue. Expression of MMP/TIMP mRNA was determined by quantitative PCR (Taqman ® ). Additionally paraffin sections of the left ventricular myocardium were stained with Sirius Red to quantify cardiac fibrosis in percent of visual field. RESULTS: (see table1 ) In summary, expression of myocardial MMP-2 and MMP-9 increased, whereas TIMP-1 decreased throughout life in diabetic and non-diabetic animals. However, expression of MMP-2 and MMP-9 was significantly diminished in ZDF compared to ZL rats during various stages of diabetes. TIMP-1 expression was lower in diabetic animals only in the prediabetic stage. Similar results were found in quantitative RT-PCR. The relative amount of fibrosis in left ventricular myocardium was markedly enhanced in late stage of diabetes (ZDF 41% fibrosis/visual field vs. ZL 18%). CONCLUSION: The observed results may play a distinctive role in the remodelling processes in late stages of disease. The regulation of expression of MMPs may, therefore, be a useful therapeutic strategy to manage diabetic cardiomyopathy. Table 1 )

Thyroid Hormone Therapy and Incident Stroke

2021 ◽  
Author(s):  
Maria Papaleontiou ◽  
Deborah A Levine ◽  
David Reyes-Gastelum ◽  
Sarah T Hawley ◽  
Mousumi Banerjee ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Thyroid Hormone ◽  
Hormone Treatment ◽  
Population Based ◽  
Thyroid Stimulating Hormone ◽  
Prior History ◽  
Veterans Health ◽  
Health Administration ◽  
Free T4 ◽  
Increased Risk

Abstract Context Stroke is a leading cause of death and disability and there is a need to identify modifiable risk factors. Objective Determine the relationship between thyroid hormone treatment intensity and incidence of atrial fibrillation and stroke. Design Retrospective cohort study using data from the Veterans Health Administration between 2004 and 2017, with a median follow-up of 59 months. Setting Population-based. Participants 733,208 thyroid hormone users aged ≥18 years with at least two thyroid stimulating hormone (TSH) measurements between thyroid hormone initiation and incident event or study conclusion (406,030 thyroid hormone users with at least two free T4 measurements). Main Outcome Measures Incident atrial fibrillation and stroke. Results Overall, 71,333/643,687 (11.08%) participants developed incident atrial fibrillation and 41,931/663,809 (6.32%) stroke. In multivariable analyses controlling for pertinent factors such as age, sex and prior history of atrial fibrillation, low TSH or high free T4 levels (i.e., exogenous hyperthyroidism; e.g., TSH<0.1 mIU/L, OR 1.33, 95% CI 1.24-1.43) and high TSH or low free T4 levels (i.e., exogenous hypothyroidism; e.g., TSH>5.5 mIU/L, OR 1.29, 95% CI 1.26-1.33; free T4<0.7 ng/dL, OR 1.29, 95% CI 1.22-1.35) were associated with higher incidence of stroke compared to euthyroidism (TSH >0.5-5.5 mIU/L and free T4 0.7-1.9 ng/dL). Risk of developing atrial fibrillation and stroke was cumulative over time for both patients with exogenous hyperthyroidism and hypothyroidism. Conclusions Both exogenous hyper- and hypothyroidism were associated with increased risk of stroke, highlighting the importance of patient medication safety.

Genesis of Statins

2009 ◽  
Author(s):  
Jie Jack Li
Keyword(s):  
Heart Disease ◽  
Thyroid Hormone ◽  
Large Scale ◽  
Hormone Treatment ◽  
Blood Cholesterol ◽  
Heart Attacks ◽  
Cholesterol Levels ◽  
The 1950S ◽  
Loss Of Libido ◽  
Artery Disease

As evidence grew that high blood cholesterol levels were linked to heart disease, scientists in both academia and industry began to look for drugs to lower cholesterol as early as the 1950s. Before Akira Endo discovered the first statin, mevastatin, in the 1970s, many things, including hormones, vitamins, and resins, were tried to lower cholesterol. Some worked, and some did not. Thyroid hormone was one of the fi st drugs used for that purpose. The cholesterol-lowering properties of dextro-thyroxine were discovered by serendipity. At one point, surgical removal of part of the thyroid gland had been used to relieve angina, the pain brought on by exercise in coronary artery disease. Doctors observed that thyroid removal also raised the blood cholesterol level, which in turn sped up arterial degeneration. By deduction, the doctors reasoned that taking thyroid hormone should then decrease blood cholesterol levels. Initial clinical trials proved this theory, and dextro-thyroxine was used to lower cholesterol beginning in the 1950s, when thyroid extract became a standard treatment for hypercholesterolemic (high cholesterol) patients. Unfortunately, too much thyroid hormone made patients tremble all the time. Later, a large-scale, long-term clinical trial named the “Coronary Drug Project” established the association of dextro-thyroxine with ischemic heart disease as a severe side eff ect in men. As a consequence, thyroid hormone treatment was discontinued. Women, in contrast to men, enjoy natural cardiac protection through the action of the female sex hormones, the estrogens. In 1930, a minute quantity of estrogen was isolated from the ovaries of 80,000 sows. In the 1950s, reports appeared that estrogen could lower blood cholesterol levels even more effectively than nicotinic acid, another anticholesterol drug used at the time. Unfortunately, men on estrogen for too long began to develop feminine traits, including breast enlargement and loss of libido, and other side effects, although they did acquire relative immunity from heart attacks until late in life. Due to the lack of safe and effiicacious drugs, some doctors seemed willing to take their chances with estrogens.

Effect of L-Triiodothyronine and Chlorpromazine on Ankle Reflex Time and a Clinical Thyroid Scale in Schizophrenics and Controls

1968 ◽  
Vol 114 (509) ◽  
pp. 451-457
Author(s):  
Eric D. West ◽  
C. J. S. Walter
Keyword(s):  
Genetic Polymorphism ◽  
Thyroid Hormone ◽  
Hormone Treatment ◽  
Treatment Benefits ◽  
Schizophrenic Patients ◽  
Reflex Time

Claims have been made that thyroid hormone treatment benefits some schizophrenic patients. Earlier studies reported the use of dried thyroid in a dose of 48 gr. (2·9G) daily in a schizophrenic (Hoskins and Sleeper, 1929) and in other psychiatric states up to 60 gr. (3·6G) daily (Minski, 1927), but recent papers describe the use of l-triiodothyrgnine in place of dried thyroid in treating schizophrenics (Lochner, Scheuing and Flach, 1963; Flach, Celian and Rawson, 1958). Huxley, Mayr, Osmond and Hoffer (1964) believe that schizophrenics are more resistant to the effects of some physiological substances, including thyroxine, as part of a genetic polymorphism.

Sign in / Sign up

Export Citation Format

Share Document